Petros Pharmaceuticals Inc. has announced a strategic corporate reorganization involving the deconsolidation of its wholly owned subsidiary, Metuchen Pharmaceuticals LLC. This move is aimed at strengthening Petros' financial position by enhancing its balance sheet, increasing stockholders' equity, and significantly reducing consolidated debt. The decision is part of a broader strategy to streamline operations and improve financial flexibility. Petros Pharmaceuticals is focused on expanding consumer access to medication through over-the-counter drug development programs. The company is also in the process of appealing Nasdaq's decision to delist its common stock, and it believes this reorganization, along with other initiatives, demonstrates substantial progress toward regaining compliance. More details on the financial impact of this reorganization will be disclosed in future filings with the Securities and Exchange Commission.